EP0757687A1 - Derives tricycliques antagonistes de 5ht2c et de 5ht2b - Google Patents

Derives tricycliques antagonistes de 5ht2c et de 5ht2b

Info

Publication number
EP0757687A1
EP0757687A1 EP95911322A EP95911322A EP0757687A1 EP 0757687 A1 EP0757687 A1 EP 0757687A1 EP 95911322 A EP95911322 A EP 95911322A EP 95911322 A EP95911322 A EP 95911322A EP 0757687 A1 EP0757687 A1 EP 0757687A1
Authority
EP
European Patent Office
Prior art keywords
dihydro
formula
hydrogen
alkyl
pyridylcarbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95911322A
Other languages
German (de)
English (en)
Inventor
Francis D. SmithKline Beecham Pharm. KING
Peter. SmithKline Beecham Pharmaceuticals HAM
Ian T. SmithKline Beecham Pharm. FORBES
Graham E. SmithKline Beecham Pharm. JONES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9408097A external-priority patent/GB9408097D0/en
Priority claimed from GB9410506A external-priority patent/GB9410506D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0757687A1 publication Critical patent/EP0757687A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • This invention relates to compounds having pharmacological activity, to a process for their preparation, to compositions containing them and to their use in the treatment of mammals.
  • WO 94/04533 (SmithKline Beecham pic) describes indole and indoline derivatives which are described as possessing 5HT2C receptor antagonist activity.
  • a structurally distinct class of compounds has now been discovered, which have been found to have 5HT2C receptor antagonist activity. Some or all of the compounds of the . invention also exhibit 5HT2B antagonist activity.
  • 5HT2C/2B receptor antagonists are believed to be of potential use in the treatment of CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
  • CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
  • Compounds of the invention are also expected to be of use in the treatment of certain GI disorders such as IBS as well as microvascular diseases such as macular oedema and retinopathy.
  • the present invention provides a compound of formula (I) or a salt thereof:
  • P represents phenyl, a quinoline or isoquinoline residue, or a 5- or 6-membered aromatic heterocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur;
  • J represents a bicyclic aromatic or partially saturated aromatic ring system
  • R! and R 2 are independently hydrogen, halogen, hydroxy, oxygen, or C ⁇ . alkyl optionally substituted by one or more halogen atoms;
  • R is hydrogen, Ci _g alkyl, C ⁇ _ alkylthio, halogen, nitro, cyano, CF3, NR8R9, ( ⁇ R* ,
  • R ⁇ , R9 and R 12 are independently hydrogen, C ⁇ . alkyl or arylC ⁇ _6alkyl; R5 is hydrogen or Ci _g alkyl; n is 2 or 3; and the groups R ⁇ and R* 4 are independendy hydrogen or Ci.g alkyl, provided that: P is not a heterocyclic group when J forms a benzothiophene ring.
  • alkyl groups can be straight chain or branched and are preferably C1.3 alkyl, such as methyl, ethyl, n- and iso- propyl.
  • Rl and R 2 are independently hydrogen, halogen, hydroxy, oxygen, or
  • Ci .g alkyl optionally substituted by one or more halogen atoms.
  • R and R 2 are both hydrogen.
  • R 4 is hydrogen, C ⁇ . alkyl, C j .g alkylthio, halogen, CF3, NR ⁇ R9 0 r
  • OR* 2 where R ⁇ , R9 and R* 2 are independently hydrogen, C1.5 alkyl or arylCi . ⁇ alkyl.
  • R 4 is hydrogen
  • R ⁇ is hydrogen or Cj.g alkyl.
  • R ⁇ is hydrogen.
  • P represents phenyl, a quinoline or isoquinoline residue, or a 5- or 6- membered aromatic heterocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur. Suitable moieties when the ring P is a 5-membered aromatic heterocyclic ring include, for example, isothiazolyl, isoxazolyl, thiadiazolyl and triazolyl.
  • Suitable moieties when the ring P is a 6-membered aromatic heterocyclic ring include, for example, pyridyl, pyrimidyl or pyrazinyl.
  • P is a quinoline or isoquinoline residue
  • the urea moiety can be attached at any position of the ring, preferably to the 4-position.
  • P is a 6-membered heterocyclic ring, most preferably a 3-pyridyl group.
  • the urea moiety can be attached to a carbon or any available nitrogen atom of the ring P, preferably it is attached to a carbon atom.
  • J represents a bicyclic aromatic or partially saturated ring system.
  • J represents a quinoline, tetrahydroquinoline, indazole, benzothiophene, dihydrobenzothiophene, indene, indane, benzothiazole, benzofuran or dihydrobenzofuran ring.
  • J is quinoline, tetrahydroquinoline, benzothiophene, benzofuran or indane.
  • the group -(CR13 14) ⁇ _ f orm s an ethylene or propylene group each of which can be substituted by C ⁇ galkyl.
  • the group -(CRl3Rl ) n _ can be attached to the 5- or 7-positions of the ring J, with the urea linkage attached to the 6-position.
  • the group -(CR13R14) ⁇ _ can i so be attached to the 2- or 4-positions of the ring J, with the urea linkage attached to the 3-position.
  • the group -(CRl3Rl4) n _ C an be attached to the 4- or 6-positions, with the urea linkage attached to the 5-position, or -(CR ⁇ :3 R 14 ) n - can be attached to the 5- or 7-positions, with the urea linkage attached to the 6-position.
  • the group -(CR ⁇ Rl4) n _ j s ethylene.
  • Particularly preferred compounds of formula (I) include: l-(3-Pyridylcarbamoyl)-2,3-dihydro-lH-pyrrolo [2,3-g] quinoline, 2-Methyl-6,7-dihydro-5-(3-pyridylcarbamoyl)-furo[2,3-f]indole, l-(3-Pyridylcarbamoyl)-2,3-dihydropyrrolo-[2,3-f]-indene, 2,3-Dihydro- 1 -(3-pyridylcarbamoyl)-pyrrolo[3,2-b]quinoline, 5,6-Dihydro-3-methyl-N-(3-pyridyl)-furo[3,2-f]indole-7-carboxamide, 2,2-Dimethyl-2,3,6,7-tetrahydro-N-(3-pyridyl)furo[2,3-f]in
  • the compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
  • acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
  • Certain compounds of formula (I) may also form N-oxides or solvates such as hydrates, and the invention also extends to these forms. When referred to herein, it is understood that the term 'compound of formula (I)' also includes these forms.
  • Certain compounds of formula (I), for example those where P is pyridyl and R 4 is hydroxy or NR ⁇ R9 and at least one of R ⁇ and R ⁇ are hydrogen, may exist tautomerically in more than one form. The invention extends to these and any other tautomeric forms and mixtures thereof.
  • Certain compounds of formula (I) are capable of existing in stereoisomeric forms including enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates.
  • the different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecif c or asymmetric synthesis.
  • the present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises the coupling of a compound of formula (II);
  • a and R" contain the appropriate functional group(s) necessary to form the moiety, -NR ⁇ CO when coupled, wherein R ⁇ ' is R ⁇ as defined in formula (I) or a group convertible thereto, n, J and P as defined in formula (I), and the variables R , R 2 , R 4 R 13 and R 14 ' are R 1 , R 2 , R 4 , R 13 and R 14 respectively, as defined in formula (I), or groups convertible thereto, and thereafter optionally and as necessary and in any appropriate order, converting any R*', R 2 ', R 4 ', R ⁇ ', R 3 ' nd R14' an( j wnen otner man R 1 , R 2 , R 4 , R5, Rl3 and R1 4 respectively to R 1 , R 2 , R 4 , R 5 , R 13 and R 14 , interconverting Rl, R 2 , R 4 , R ⁇ , R1 and R* 4 , and forming a pharmaceutically acceptable salt thereof.
  • Suitable examples of groups A and R ⁇ include:
  • A is -NR5'C0L and R 6 is -H
  • A is -NHR 5 ' and R 6 is COL, or
  • A is halogen and R 6 is -CONHR 5 ', wherein R ⁇ ' is as defined above and L is a leaving group.
  • suitable leaving groups L include imidazole, halogen such as chloro or bromo or phenoxy or phenylthio optionally substituted for example with halogen.
  • reaction is suitably carried out in an inert solvent for example dichloromethane or toluene at ambient temperature.
  • reaction is suitably carried out in an inert solvent such as dichloromethane at ambient temperature optionally in the presence of a base, such as triethylamine or in dimethylformamide at ambient or elevated temperature.
  • an inert solvent such as dichloromethane at ambient temperature
  • a base such as triethylamine or in dimethylformamide at ambient or elevated temperature.
  • R 4 ' which are convertible to R 4 alkyl groups include acyl groups which are introduced conventionally and may be converted to the corresponding alkyl group by conventional reduction, such as using sodium borohydride in an inert solvent followed by hydrogenolysis in an inert solvent. Hydrogen substituents may be obtained from alkoxycarbonyl groups which may be converted to hydrogen by hydrolysis and decarboxylation.
  • R 4 is hydroxy it is preferably protected in the compound of formula (II) as, for example, benzyl which is removed by hydrogenation.
  • Suitable examples of a group R ⁇ ' which is convertible to R ⁇ include alkoxycarbonyl and benzyl or para-methoxybenzyl which are converted to R ⁇ is hydrogen using conventional conditions.
  • R 4 halo and R /R 2 halo groups may be introduced by selective halogenation of the rings P or J respectively using conventional conditions.
  • salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.
  • N-oxides may be formed conventionally by reaction with hydrogen peroxide or percarboxylic acids.
  • Compounds of formula (I) and their pharmaceutically acceptable salts have 5HT2C receptor antagonist activity, and certain compounds show 5HT2B antagonist activity.
  • Compounds of formula (I) are therefore believed to be of potential use in the treatment of CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
  • Compounds of the invention are also expected to be of use in the treatment of certain GI disorders such as IBS.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders.
  • the invention further provides a method of treatment or prophylaxis of the above disorders, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis the above disorders.
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • the composition may contain from 0.1% to 99% by weight, preferably from 10 to
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 70.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.01 to 100 mg; and such therapy may extend for a number of weeks or months.
  • 6-Nitroindoline (6.50g, 40 mmol) and triethylamine (6.6 ml, 47 mmol) were stirred in i dichloromethane (65 ml) as trifluoroacetic anhydride (6.6 ml, 47 mmol) was added dropwise. This mixture was stirred for 0.75h, and water (100 ml) was added. After stirring for 10 min, the mixture was acidified with 5M HC1, and separated. The organic portion was washed with brine, dried (Na2SO4) and evaporated to give the title compound (9.64g, 93%) as a yellow-brown solid.
  • 6-Amino-l-trifluoroacetylindoline (D2) (2.98g, 13 mmol) was stirred in water (30 ml) as c H2SO4 (3 ml) was added dropwise. The solution was cooled to 0° C, and NaNO2 (0.98g, 14 mmol) in water (10 ml) was added dropwise, maintaining the temperature ⁇ 0° C. The mixture was stirred for 5 min, and then transferred to a boiling solution of CUSO4.5H2O (13.0g, 52 mmol) in water (50 ml). The mixture was boiled for 5 min and cooled, and the black solid was filtered off and air-dried. Chromatography on silica gel, eluting with 0- 5% methanol in chloroform, gave the title compound (l.Olg, 67%) as a dark brown solid.
  • Trifluoroacetic acid (4ml) was added to a mixture of 6,7-dihydro-5-(3-pyridylcarbamoyl)- 5H-thieno[2,3-f]indole (Reference WO 94/22871) (l.Og) and triethylsilane (1.63ml), with heating at 50°C. After 140h, the cooled mixture was neutralised with aqueous sodium carbonate solution and the aqueous layer extracted with diethyl ether. The organic phase was dried (Na2SO4), and concentrated under reduced pressure. The residue was chromatographed on silica eluting with 1% ethanol and chloroform to afford title compound (340mg).
  • the title compound was prepared from D24 in 76% yield using modified Sandmeyer conditions.
  • the tide compound was prepared from D26 using standard hydrogenation conditions in 92% yield as a white solid.
  • N-methyl-6-(chlorosulphonyl)indolinel was converted to the title compound in 50% yield using the method of Olah et ⁇ / 2 .
  • Nicotinoyl azide (0.14g, 0.94 mmol) was stirred at reflux under Ar in dry toluene (5 ml) for 0.75h, and cooled to ambient temperature. This was then filtered dirough cotton wool into a stirred solution of 5,6-dihydro-3-methylfuro[3,2-f]indole (D6) (0.15g, 0.86 mmol) in dichloromethane (5 ml). After stirring for 15 min, the suspension was cooled in ice, and the precipitate was filtered off and dried. This gave the title compound (0.15g, 59%) as a tan powder.
  • This material was prepared from 2,2-dimemyl-2,3,6,7-tetrahydrofuro[2,3-f]indole (D12, 0.147g, 0.77mmol), following the procedure of Example 1. This gave the title compound (0.147g, 61%) as a white powder.
  • the tide compound was prepared in die usual manner from 5-methyl-2,3,5,6,7,8- hexahydro-lH-pyrrolo-[2,3-g]quinoline (D22) (0.64g, 3m moles) and 3-pyridylisocyanate (0.4g, 3 mmoles) followed by treatment with oxalic acid and recrystallisation from methanol/diethylether. This gave (E8) (0.42g, 31%) m.p.l93-194°C
  • 5-HT2C antagonists may have a number of therapeutic indications including the treatment of anxiety, migraine, depression, feeding disorders and obsessive compulsion disorders. (Curzon and Kennett, 1990; Fozard and Gray, 1989) and Alzheimer's Disease (Lawlor, 1989, J. Arch. Gen. Psychiat. Vol. 46 p.542).
  • the affinity of test drugs for the 5-HT2C binding site can be determined by assessing dieir ability to displace [ H]-mesulergine from 5-HT2C clones expressed in 293 cells (Julius et al, 1988). The method employed was similar to that of Pazos et al, 1984. The cells suspension (400ml) was incubated widi [ 3 H]-mesulergine (0.5nM) in Tris HCl buffer (pH 7.4) at 37°C for 30 minutes. Non-specific binding was measured in d e presence of mianserin (10 " ⁇ M). Ten concentrations of test drug (3 x 10 ⁇ 9 to 10 "4 M final concentration) were added in a volume of 50ml. The total assay volume was 500ml.
  • Kd Affinity of mesulergine for 5-HT2C binding sites.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés de la formule (I), leurs procédés de préparation et leur utilisation en tant qu'agents du système nerveux central. Dans cette formule, P représente phényle, un reste de quinoline ou d'isoquinoline, ou un cycle hétérocyclique aromatique à 5 ou 6 chaînons contenant jusqu'à trois hétéroatomes choisis parmi azote, oxygène ou soufre; J représente un système de cycles bicycliques aromatiques ou partiellement saturés; R1 et R2 représentent indépendamment hydrogène, halogène, hydroxy, oxygène ou alcoyle C¿1-6? éventuellement substitué par un ou plusieurs atomes d'halogène; R?4¿ représente hydrogène, alcoyle C¿1-6?, alcoylthio C1-6, halogène, nitro, cyano, CF3, NR?8R9, CO¿2R?12, CONR12 ou OR12¿, dans lesquels R?8, R9 et R12¿ représentent indépendamment hydrogène, alcoyle C¿1-6?, ou arylalcoyle C1-6; R?5¿ représente hydrogène ou alcoyle C¿1-6?; n vaut 2 ou 3; et les groupes R?13 et R14¿ représentent indépendamment hydrogène ou alcoyle C¿1-6?, à condition que P ne soit pas un groupe hétérocyclique lorsque J forme un cycle benzothiophène.
EP95911322A 1994-04-23 1995-03-09 Derives tricycliques antagonistes de 5ht2c et de 5ht2b Withdrawn EP0757687A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9408097A GB9408097D0 (en) 1994-04-23 1994-04-23 Novel compounds
GB9408097 1994-04-23
GB9410506A GB9410506D0 (en) 1994-05-25 1994-05-25 Novel compounds
GB9410506 1994-05-25
PCT/EP1995/000901 WO1995029177A1 (fr) 1994-04-23 1995-03-09 Derives tricycliques antagonistes de 5ht2c et de 5ht2b

Publications (1)

Publication Number Publication Date
EP0757687A1 true EP0757687A1 (fr) 1997-02-12

Family

ID=26304761

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95911322A Withdrawn EP0757687A1 (fr) 1994-04-23 1995-03-09 Derives tricycliques antagonistes de 5ht2c et de 5ht2b

Country Status (3)

Country Link
EP (1) EP0757687A1 (fr)
JP (1) JPH09512025A (fr)
WO (1) WO1995029177A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0807104A2 (fr) * 1995-02-02 1997-11-19 Smithkline Beecham Plc Composes heterocycliques possedant une activite antagoniste vis-a-vis du recepteur de 5ht 2c?
JP2001508767A (ja) * 1996-12-02 2001-07-03 藤沢薬品工業株式会社 ５―ｈｔ拮抗作用を有するインドール―ウレア誘導体
GB9818641D0 (en) * 1998-08-26 1998-10-21 Rh Ne Poulenc Rorer Limited Chemical compounds
ES2297943T3 (es) 1998-12-23 2008-05-01 Aventis Pharma Limited Dihidro-benzo(1,4)oxacinas y tetrahidroquinoxalinas.
CA2382413A1 (fr) * 1999-08-20 2001-03-01 Shigenori Ohkawa Derives dihydrobenzofuran tricycliques, leur procede de preparation et agents
FR2807754A1 (fr) * 2000-04-13 2001-10-19 Adir Nouveaux derives de cyclobuta-indole carboxamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2807753B1 (fr) * 2000-04-13 2002-06-07 Adir Nouveaux derives d'heterocycloalkylbenzocyclobutane et d'heteroarylbenzocyclobutane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2837823B1 (fr) * 2002-03-27 2005-04-08 Servier Lab Nouveaux derives d'indoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4704693A (en) * 1992-08-20 1994-03-15 Smithkline Beecham Plc Condensed indole derivatives as 5HT-2C and 5HT-2B antagonists
WO1994014801A1 (fr) * 1992-12-29 1994-07-07 Smithkline Beecham Plc Derives heterocycliques de l'uree antagonistes de 5ht2c et 5h¿2b?
GB9306460D0 (en) * 1993-03-29 1993-05-19 Smithkline Beecham Plc Novel compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9529177A1 *

Also Published As

Publication number Publication date
WO1995029177A1 (fr) 1995-11-02
JPH09512025A (ja) 1997-12-02

Similar Documents

Publication Publication Date Title
US6849640B2 (en) Therapeutic 1H-pyrido [4,3-b] indoles
US7576087B2 (en) Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
FI96768C (fi) Menetelmä valmistaa farmakologisesti arvokasta bentso/5,6/sykloheptapyridiiniä
WO1996011929A1 (fr) Derives biheteroaryl-carbonyles et carboxamides possedant une activite antagoniste de 5ht 2c/2b
AU2003248590A1 (en) Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists
AU2003281194A1 (en) Mchir antagonists
EP0705832B1 (fr) Modulateurs serotonergiques
NZ254785A (en) Heterocyclically-condensed indoles and medicaments
AU2006298164A1 (en) Novel fused pyrrole derivative
KR20100124279A (ko) (디히드로)피롤로[2,1-ａ]이소퀴놀린
NZ230068A (en) Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
EP1923387B1 (fr) Dérivé d'acylguanidine ou sel de celui-ci
US5563147A (en) Serotonerbic tetrahydropyridoindoles
EP0757687A1 (fr) Derives tricycliques antagonistes de 5ht2c et de 5ht2b
JPH08502273A (ja) ５−ｈｔ▲下４▼レセプターアンタゴニスト用複素環式エステルまたはアミド
US6313145B1 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists
JP6267334B2 (ja) ５−ｈｔ６拮抗薬としてのピロロキノリン誘導体、それらの製造方法および使用
WO2023272701A1 (fr) Formes cristallines de 3-{4-[(2r)-2-aminopropoxy]phényl}-n-[(1r)- 1-(3-fluorophényl) éthyl]imidazo[1,2-b]pyridazin-6-amine et ses sels
TW202310845A (zh) 雜芳基衍生化合物及其用途
SK282706B6 (sk) Indolínové deriváty, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukt
KR20000029564A (ko) 5ＨＴ2ｃ길항제및Ｄ2길항제를함유하는약제학적조성물
WO2000006575A2 (fr) Nouveaux composes
EP0743946A1 (fr) Indoles condenses a titre d'antagonistes des recepteurs de 5ht 2b?
JP3031634B2 (ja) Ｄ１アンタゴニスト／ｄ２アンタゴニスト及び５ｈｔ２−セロトニンアンタゴニストとしてのピペリジニル置換メタノアントラセン
TW202321231A (zh) 作為sting拮抗劑之小分子尿素衍生物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961018

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991001